References
- Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-5
- Vergnenegre A, Corre R, Berard H, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol 2011;6:161-8
- Alifrangis C, Krell J, Stebbing J. The pharmacoeconomics of spiralling cancer drug costs – is there a viable solution? Eur J Cancer 2011;47:1285-6
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80
- Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14:1165-74
- National Cancer Institute. National Institute of Health. Non-Small Cell Lung Cancer Treatment. http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page11. Accessed October 16, 2013.
- Carrato A, Vergnenégre A, Thomas M, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin 2014;30:447-61
- Ihbe-Heffinger A, Paessens B, Berger K, et al. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care - an observational analysis on non-small-cell lung cancer patients. Support Care Cancer 2013;21:1665-75
- Paessens BJ, von Schilling C, Berger K, et al. Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 2011;22:2310-9
- Banz K, Bischoff H, Brunner M, et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 2011;74:529-34
- Horgan AM, Bradbury PA, Amir E, et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol 2011;22:1805-11
- Chouaid C, Moser A, Coudray-Omnes C, et al. Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer [in French]. Rev Mal Respir 2008;25:1096-103
- Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
- Ihbe-Heffinger A, Paessens BJ, von Schilling C, et al. Management of febrile neutropenia – a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie 2011;34:241-6
- Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010;102:298-306
- Novello S, Pimentel FL, Douillard JY, et al. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1602-8